Creating a new neuromodulator category.
Revance® is developing the first innovative neuromodulator product in nearly 30 years: DaxibotulinumtoxinA for Injection (DAXI). DAXI combines a highly purified botulinum toxin type A molecule with a proprietary stabilizing excipient peptide technology to potentially produce the first long-acting neuromodulator formulated without human serum albumin.
Revance anticipates commercial launch in 2021 upon FDA approval.
Brands: Investigational agent, DaxibotulinumtoxinA for Injection (DAXI)